What this means
This trial is still recruiting people, and no results have been posted yet. The researchers hope the program may help prevent some age-related losses, but that is not yet shown.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 65–85
- Where
- 1 site
The science
- Registered title
- ICOPE INTENSE-K Pilot Study
- Trial ID
- NCT07048860 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Ageing
- What is tested
- ICOPE intense intervention, Ketone Ester (KE) supplementation, Placebo, Vitamin D3, OMega 3, vitamin B9, Vitamin B12, Leucin-rich whey, ICOPE Step 1
- Sponsor
- University Hospital, Toulouse
- Ages
- 65 Years to 85 Years
- Dates
- First posted Jul 3, 2025 · updated Jul 23, 2025
Registry summary
ICOPE could constitute the reference model of care for healthy aging. More specifically, our hypothesis is that the intervention implemented in ICOPE may directly or indirectly prevent immuno-senescence, the loss of mobility and the cognitive decline. In future Geroscience clinical trials, ICOPE-Intense could become a benchmark to reduce the rate of aging with a strong non-pharmacological intervention and state a reference intervention to compare with new gerotherapeutic drugs.
Sites (1)
- Cité de la santé - Hopital La Grave, Toulouse, France